| Quest – Discovery Stage Research Projects | Dr. Birgitt Schuele | CRISPR/dCas9 mutant targeting SNCA promoter for downregulation of alpha-synuclein expression as a novel therapeutic approach for Parkinson’s disease |
$1,288,415 |
| Basic Biology III | R. Jeremy Nichols | Understanding the role of LRRK2 in iPSC cell models of Parkinson’s Disease |
$1,482,822 |
| Tools and Technologies II | Dr. Birgitt Schuele | Editing of Parkinson’s disease mutation in patient-derived iPSCs by zinc-finger nucleases |
$1,327,983 |
| Research Leadership | Dennis Steindler | Stem Cell Pathologies in Parkinson’s disease as a key to Regenerative Strategies |
$0 |
| Early Translational I | Mr. James “Bill” William Langston Mr. | Using patient-specific iPSC derived dopaminergic neurons to overcome a major bottleneck in Parkinson’s disease research and drug discovery |
$3,698,646 |
